EUVIMEDObjevte EUVIMED
ÜbersichtsarbeitOpen access

Association of COVID-19 with Comorbidities: An Update

Sayan Chatterjee, Lakshmi Vineela Nalla, Monika Sharma, Nishant Sharma, Aditya A Singh, Fehmina Mushtaque Malim, Manasi Ghatage, Mohd Mukarram, Abhijeet Pawar, Nidhi Parihar, Neha Arya, Amit Khairnar iD

ACS Pharmacology & Translational Science · 2023-03-10 · 6 (3) · 334-354

DOI: 10.1021/acsptsci.2c00181 ↗

At a glance

Übersichtsarbeit in ACS Pharmacology & Translational Science, published online on 2023-02-27. Written by Sayan Chatterjee and 11 co-authors. Institution: Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Ahmedabad, Gujarat 382355, India. Cited 83 times so far (Crossref); 198 references. The full text is freely available in PubMed Central. Funded by: Department of Biotechnology, Ministry of Science and Technology, India, National Institute of Pharmaceutical Education and Research, Ahmedabad.

AbstraktBibliografické údajeCiteRelated studies

Abstract (original language)

Coronavirus disease (COVID-19) is caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) which was identified in Wuhan, China in December 2019 and jeopardized human lives. It spreads at an unprecedented rate worldwide, with serious and still-unfolding health conditions and economic ramifications. Based on the clinical investigations, the severity of COVID-19 appears to be highly variable, ranging from mild to severe infections including the death of an infected individual. To add to this, patients with comorbid conditions such as age or concomitant illnesses are significant predictors of the disease's severity and progression. SARS-CoV-2 enters inside the host cells through ACE2 (angiotensin converting enzyme2) receptor expression; therefore, comorbidities associated with higher ACE2 expression may enhance the virus entry and the severity of COVID-19 infection. It has already been recognized that age-related comorbidities such as Parkinson's disease, cancer, diabetes, and cardiovascular diseases may lead to life-threatening illnesses in COVID-19-infected patients. COVID-19 infection results in the excessive release of cytokines, called "cytokine storm", which causes the worsening of comorbid disease conditions. Different mechanisms of COVID-19 infections leading to intensive care unit (ICU) admissions or deaths have been hypothesized. This review provides insights into the relationship between various comorbidities and COVID-19 infection. We further discuss the potential pathophysiological correlation between COVID-19 disease and comorbidities with the medical interventions for comorbid patients. Toward the end, different therapeutic options have been discussed for COVID-19-infected comorbid patients.

Authors and institutions

  • Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Ahmedabad, Gujarat 382355, India.
  • Department of Pharmacy, Koneru Lakshmaiah Education Foundation, Vaddeswaram, Andhra Pradesh 522302, India.
  • Department of Translational Medicine, All India Institute of Medical Sciences (AIIMS), Bhopal, Bhopal 462020, India.
  • International Clinical Research Center, St. Anne's University Hospital Brno, Brno 602 00, Czech Republic.
  • ICRC-FNUSA Brno 656 91, Czech Republic.
  • Department of Physiology, Faculty of Medicine, Masaryk University, Kamenice 753/5, 62500 Brno, Czechia.

ORCID profiles: Amit Khairnar

Funding

  • Department of Biotechnology, Ministry of Science and Technology, India
  • National Institute of Pharmaceutical Education and Research, Ahmedabad

Cite

APA

Chatterjee, S., Nalla, L. V., Sharma, M., Sharma, N., Singh, A. A., Malim, F. M., Ghatage, M., Mukarram, M., Pawar, A., Parihar, N., Arya, N., & Khairnar, A. (2023). Association of COVID-19 with Comorbidities: An Update. ACS Pharmacology & Translational Science, 6(3), 334-354. https://doi.org/10.1021/acsptsci.2c00181

Vancouver

Chatterjee S, Nalla LV, Sharma M, Sharma N, Singh AA, Malim FM, et al. Association of COVID-19 with Comorbidities: An Update. ACS Pharmacology & Translational Science. 2023;6(3):334-354. doi:10.1021/acsptsci.2c00181

BibTeX
@article{Chatterjee2023,
  author = {Chatterjee, Sayan and Nalla, Lakshmi Vineela and Sharma, Monika and Sharma, Nishant and Singh, Aditya A and Malim, Fehmina Mushtaque and Ghatage, Manasi and Mukarram, Mohd and Pawar, Abhijeet and Parihar, Nidhi and Arya, Neha and Khairnar, Amit},
  title = {Association of COVID-19 with Comorbidities: An Update},
  journal = {ACS Pharmacology & Translational Science},
  year = {2023},
  volume = {6},
  number = {3},
  pages = {334--354},
  doi = {10.1021/acsptsci.2c00181}
}
Start for free →